ABSTRACT
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020â2022. The results of our own studies of pharmacological substances based on recombinant IFN-λ1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-λ as an effective therapeutic agent against SARS-CoV-2.
ABSTRACT
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-lambda1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-lambda as an effective therapeutic agent against SARS-CoV-2.
ABSTRACT
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-lambda1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-lambda as an effective therapeutic agent against SARS-CoV-2.
ABSTRACT
This study provides an overview of scientific results on the feasibility of using type III interferons against SARS-CoV-2. We have analyzed data obtained from the PubMed electronic database for the period 2020-2022. The results of our own studies of pharmacological substances based on recombinant IFN-lambda1 and its pegylated form are also presented. Completed and ongoing investigations allow us to position IFN-lambda as an effective therapeutic agent against SARS-CoV-2.